Hospital General Universitario De Valencia — Clinical Trial Site

214 Registered trials

76 Currently recruiting

Organisation

Hospital General Universitario De Valencia

Location

Valencia, Spain

Identifier

ORG-100023081

Address

Avenida Tres Cruces 2, 46014, Spain

Departments

#3417 - Reumatología
#3443: Medicina Interna
#4504: Cardiología
#7009:Reumatología
#93158007: Oncología
#98358007: Oncology
2810: Medicina Interna
3139: medicina interna
3417: Reumatología
3460: Servicio Dermatología
40868: Dermatología
7002: Oncología
9253: Servicio Dermatología
Allergology
Anestesiología y Reanimación
Cardiologia
Cardiology
Departamento 9
Departamento de Obstetricia y Ginecología
Department of Obstetrics and Gynecology
Dermatology
Dermatology department
Digestive
Digestive service
Endocrinology
Endocrinology & Nutrition
Endocrinology and metabolism
Endocrinology and nutrition
Endocrinology and Nutrition Department
ESP2: Oftalmología
Gastroenterología
Hematología
Hematology
Hematology Department
Hepatology
Hospital General De Valencia( #1)
Hospital General Universitario De Valencia
Infectious
infectious diseases
Infectious Diseases Service
Internal Medicine
Medica Oncology
Medical Oncology
Medical Oncology Department
N/A
NA
Neumology
OFTALMOLOGIA
Oncolgy
Oncologia
Oncología Médica
Oncology
Oncology Department
Oncology service
Ophthalmology
Rheumatology
Serv. De Reumatología
Servicio de digestivo
Servicio de Aparato Digestivo
Servicio de Dermatología
Servicio de Endocrinología y Nutrición
Servicio de Enfermedades Infecciosas
Servicio de Farmacia
Servicio de Hematología
Servicio de Hepatologia
Servicio de Neumología
Servicio de Oftalmologia
Servicio de Oncología
Servicio de Oncología Médica
Servicio de Patología Digestiva
Servicio Enfermedades Infecciosas
Surgery
Thoracic Oncology
Unidad de Hepatología
Unidad de Infecciosas
Ν/Α

Clinical trials at this site (214)

Search interface

A Study of Amivantamab in Addition to Standard of Care Agents Compared with Standard of Care in Participants With Recurrent/Metastatic Head … Recruiting

2025-521917-24-00 Treatment-Naïve Recurrent/Metastatic Head and Neck Squa 5 2026-01-21
A clinical study of MK-1084 and other treatments for lung cancer (MK-1084-007) Recruiting

2024-514500-14-00 Participants with KRAS G12C-Mutant, Advanced or Metasta 5 2025-12-15
ENGIC 06 (PRODIGE 114) – FFCD 2401 – FRUQUITAS Randomized phase III trial to compare trifluridine/tipiracil + Fruquintinib versus triflurid… Recruiting

2025-522395-92-00 metastatic oeso-gastric adenocarcinoma 5 2025-12-15
A study to evaluate the impact on metastases-free survival with the addition of saruparib vs placebo to a standard radiotherapy androgen dep… Recruiting

2024-513586-39-00 Prostate Cancer 5 2025-12-10
Phase II study of tarlatamab as a follow-up treatment after chemo and radiation in patients with small cell lung cancer (SCLC) who cannot re… Recruiting

2024-515201-26-00 Small cell lung cancer (SCLC) 4 2025-12-09
A Study to Learn About the Study Medicine Called PF-08046054/SGNPDL1V Versus Docetaxel in Adult Participants with Previously-treated Program… Recruiting

2025-521281-97-00 Non-Small Cell Lung Cancer (NSCLC) 5 2025-12-02
A study to evaluate the safety and efficacy of two dose levels of ONO-4578 with Opdivo®, in combination with mFOLFOX6 and bevacizumab versus… Recruiting

2024-519590-19-00 PD-L1 positive advanced colorectal cancer 4 2025-11-25
A clinical study of sac-TMT in people with breast cancer (MK-2870-032) Recruiting

2024-520190-12-00 Breast Cancer: triple negative breast cancer (TNBC) and 5 2025-11-10
A trial to see if ficerafusp alfa given with pembrolizumab can treat participants with head and neck cancer. Recruiting

2024-519654-37-00 Recurrent or Metastatic Head and Neck Squamous Cell Car 10 2025-11-07
A Phase 2 Study of the Effects and Safety of PF-07328948 in Adults with Heart Failure (BRANCH-HF) Recruiting

2024-518438-94-00 Heart failure 4 2025-10-24
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with moderate to severe hid… Recruiting

2025-520564-17-00 Hidradenitis suppurativa (HS) 5 2025-10-16
A Phase 3 study of NBTXR3 with or without cetuximab in LA-HNSCC Recruiting

2024-520386-31-00 Locally Advanced Head & Neck Squamous Cell Carcinoma 5 2025-09-22
A study to evaluate acalabrutinib, in combination with the R-CHOP standard of care, for previously untreated mantle cell lymphoma in Spain. Recruiting

2025-521152-34-00 mantle cell lymphoma (MCL) 4 2025-09-04
ENGIC 01 - COLOSOTO: A single-arm phase II study evaluating 5-fluorouracil plus Panitumumab (anti-EGFR) and Sotorasib (KRAS G12C inhibitor) … Recruiting

2024-514030-20-00 colorectal cancer 4 2025-08-29
A study to test whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure and a weak pumping functio… Recruiting

2024-519525-38-00 Heart failure 5 2025-08-22
A clinical study of sacituzumab tirumotecan with or without pembrolizumab in people with breast cancer (MK-2870-011) Recruiting

2024-516834-36-00 Locally recurrent unresectable or metastatic TNBC with 5 2025-07-08
Study of the treatment of patients with non-small cell lung cancer with metastasis with Cemiplimab and subsequent treatment with Cemiplimab … Recruiting

2024-518812-38-00 Non-small cell lung cancer (NSCLC) 4 2025-07-02
Safety, efficacy, and pharmacokinetics of BNT327 in combination with chemotherapy and other investigational agents for lung cancer Recruiting

2024-515764-31-00 Non-small cell lung cancer 10 2025-06-13
Phase II clinical trial of chemotherapy + atezolizumab for stage IIIa and IIIb non-small cell lung cancer followed by atezolizumab as adjuva… Recruiting

2024-515984-68-00 Non-small cell lung cancer (NSCLC) 4 2025-05-20
Phase II, single arm, multicentre clinical trial to evaluate the activity of encorafenib plus binimetinib followed by Cemiplimab And Fianlim… Recruiting

2024-513375-40-00 Melanoma 4 2025-05-16
Is CT 01 safe to use alone or combined with Everolimus for inoperable advanced liver cancer? Recruiting

2024-511435-10-00 Hepatocellular Carcinoma 1 2025-04-30
PRESERVE-003: ONC-392 (Study Drug) Versus Docetaxel (Standard of Care) in Metastatic Non-small Cell Lung Cancer That Progressed on PD-1/PD-L… Recruiting

2023-505311-20-01 Metastatic Non-Small Cell Lung Cancer 5 2025-03-21
Phase II study of Roginolisib in UM patients Recruiting

2024-514333-37-00 Advanced Metastatic Ocular/Uveal Melanoma 4 2025-02-25
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients with Operable No… Recruiting

2023-509806-31-00 Non-Small Cell Lung Cancer 4 2025-02-11